Clinical trial results:
AZD9291, an irreversible EGFR-TKI, in relapsed EGFR-mutated non-small cell lung cancer patients previously treated with an EGFR-TKI, coupled to extensive translational studies.

Summary

EudraCT number	2015-000307-10
Trial protocol	NO DK FI LT SE
Global end of trial date	15 March 2023

Results information

Result version number	v1 (current)
This version publication date	20 July 2025
First version publication date	20 July 2025
Summary attachment (see zip file)	TREM publication (200319 TREM_Lung cancer.pdf)

Trial information

Trial identification

Sponsor protocol code	TREM

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02504346
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Oslo university hospital
Sponsor organisation address	Ullernchaussen 70, Oslo, Norway, 0379
Public contact	Clinical Trial Unit, Oslo university hospital, 47 99723094, ot.brustugun@gmail.com
Scientific contact	Clinical Trial Unit, Oslo university hospital, 47 32862464, ot.brustugun@gmail.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	10 March 2020
Is this the analysis of the primary completion data?	Yes
Primary completion date	07 January 2019
Global end of trial reached?	Yes
Global end of trial date	15 March 2023
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

Efficacy evaluation of AZD9291

Protection of trial subjects:

Regular follow up visits with safety registration and radiology assessment to ensure dose reduction and/or pause from study treatment if non-acceptable adverse events or to discover progression of disease.

Background therapy: -

Evidence for comparator:

No comparator, single arm design

Actual start date of recruitment	15 July 2015
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Norway: 65
Country: Number of subjects enrolled	Sweden: 45
Country: Number of subjects enrolled	Denmark: 50
Country: Number of subjects enrolled	Finland: 25
Country: Number of subjects enrolled	Lithuania: 14
Worldwide total number of subjects	199
EEA total number of subjects	199

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0

Adults (18-64 years)	91
From 65 to 84 years	104
85 years and over	4

Subject disposition

Recruitment

Recruitment details:

Recruitment period July 2015 to November 2017, participating countries Norway, Denmark, Sweden, Finland, Lithuania

Pre-assignment

Screening details:

Patients with advanced lung cancer and a documentet EGFR-mutation who had progressed on at least one previous EGFR-TKI could be enrolled.

Period 1

Period 1 title	Baseline
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Treatment arm

Arm description:

All patients received study treatment (single arm design)

Arm type	Experimental
Investigational medicinal product name	Osimertinib
Investigational medicinal product code	AZD9291
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

80 mg orally one daily

Arm title	Treatment arm2

Arm description: -

Arm type	Experimental
Investigational medicinal product name	Osimertinib
Investigational medicinal product code	AZD9291
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

80 mg orally one daily

Number of subjects in period 1	Treatment arm	Treatment arm2
Started	198	1
Completed	198	1

Period 2	
Period 2 title	Overall trial
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Arm title	Treatment arm

Arm description:

All patients received study treatment (single arm design)

Arm type	Experimental
Investigational medicinal product name	Osimertinib
Investigational medicinal product code	AZD9291
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

80 mg orally one daily

Number of subjects in period 2	Treatment arm
Started	199
Completed	199

Baseline characteristics

Reporting groups	
Reporting group title	Baseline

Reporting group description: -

Reporting group values	Baseline	Total	
Number of subjects	199	199	
Age categorical Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	0	0	
Adolescents (12-17 years)	0	0	
Adults (18-64 years)	91	91	
From 65-84 years	104	104	
85 years and over	4	4	
Gender categorical Units: Subjects			
Female	139	139	
Male	60	60	

End points

End points reporting groups	
Reporting group title	Treatment arm
Reporting group description: All patients received study treatment (single arm design)	
Reporting group title	Treatment arm2
Reporting group description: -	
Reporting group title	Treatment arm
Reporting group description: All patients received study treatment (single arm design)	

Primary: Objective response rate	
End point title	Objective response rate
End point description:	
End point type	Primary
End point timeframe: Primary analysis	

End point values	Treatment arm	Treatment arm2		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	191	1		
Units: Number of patients with PR or CR	191	1		

Statistical analyses

Statistical analysis title	ORR
Statistical analysis description: Ratio of patients with measurable disease achieving PR or CR	
Comparison groups	Treatment arm v Treatment arm2
Number of subjects included in analysis	192
Analysis specification	Pre-specified
Analysis type	other[1]
Parameter estimate	Ratio, single group
Point estimate	48
Confidence interval	
level	95 %
sides	2-sided
lower limit	41
upper limit	55

Variability estimate	Standard deviation

Notes:

[1] - Single arm study, analysis of proportion of patients responding to treatment

Adverse events

Adverse events information

Timeframe for reporting adverse events:

July 2015 to March 2023

Assessment type	Systematic

Dictionary used

Dictionary name	CTCAE
Dictionary version	4.0

Reporting groups

Reporting group title	Total study population

Reporting group description: -

Serious adverse events	Total study population		
Total subjects affected by serious adverse events			
subjects affected / exposed	3 / 199 (1.51%)		
number of deaths (all causes)	5		
number of deaths resulting from adverse events	0		
Gastrointestinal disorders			
Nausea			
subjects affected / exposed	1 / 199 (0.50%)		
occurrences causally related to treatment / all	58 / 58		
deaths causally related to treatment / all	0 / 0		
Diarrhoea			
subjects affected / exposed	1 / 199 (0.50%)		
occurrences causally related to treatment / all	83 / 83		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Pneumonitis			
subjects affected / exposed	1 / 199 (0.50%)		
occurrences causally related to treatment / all	8 / 8		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Total study population		
Total subjects affected by non-serious adverse events subjects affected / exposed	196 / 199 (98.49%)		
General disorders and administration site conditions Fatigue subjects affected / exposed occurrences (all)	133 / 199 (66.83%) 133		
Gastrointestinal disorders Diarrhoea subjects affected / exposed occurrences (all)	83 / 199 (41.71%) 83		
Respiratory, thoracic and mediastinal disorders Dyspnoea subjects affected / exposed occurrences (all)	87 / 199 (43.72%) 87		
Skin and subcutaneous tissue disorders Rash subjects affected / exposed occurrences (all) Paronychia subjects affected / exposed occurrences (all)	85 / 199 (42.71%) 85 83 / 199 (41.71%) 83		
Metabolism and nutrition disorders Decreased appetite subjects affected / exposed occurrences (all)	89 / 199 (44.72%) 89		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported